Polycaprolactone (PCL) is a synthetic biodegradable polymer that has been approved for use as bone graft substitutes. In this study, PCL scaffolds incorporating hydroxyapatite (HAp) particles were fabricated by combined solvent casting and particulate leaching techniques. The average pore dimension was in the range of about 480-500 microm. The porosity, water absorption, and compressive modulus of the scaffold were evaluated. The responses of primary bone cells cultured on the PCL and PCL/HAp scaffolds were examined both in vitro and invivo. In comparison with the cells grown on the PCL scaffold, those cultured on the PCL/HAp counterpart positively expressed the markers of osteogenic differentiation. Cells increased the mRNA expressions of type I collagen and osteocalcin on day 10 and demonstrated a significant increase in calcium deposition. In coherence with the in vitro appearance, histomorphometric analysis in a mouse calvarial model showed a significantly greater amount of new bone formation. The results demonstrated that the prepared PCL/HAp scaffold could be a good candidate as synthetic substitute for bone tissue engineering. (c) 2010 Wiley Periodicals, Inc. J Biomed Mater Res, 2010.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbm.a.32657 | DOI Listing |
Cell Mol Biol Lett
January 2025
Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Key Laboratory of Drug Research for Prevention and Treatment of Hyperlipidemic Diseases, Soochow University, 199 Ren'ai Road, Suzhou, 215123, Jiangsu, China.
Background: The protein cereblon (CRBN) mediates the antileukemia effect of lenalidomide (Len). Len binds to CRBN, recruits IKZF1/IKZF3, and promotes their ubiquitination and degradation, through which Len exhibits its antileukemia and antimyeloma activity. Therefore, the protein level of CRBN might affect the antiproliferative effect of Len.
View Article and Find Full Text PDFInt Dent J
January 2025
Department of Prosthodontics, Taiyuan Conatant lun Dental Hospital, Taiyuan, 030001, Shanxi, China.
Introduction And Aims: Epidemiological observational studies have explored the link between bone joint-related diseases and temporomandibular disorders (TMD), but inconsistent conclusions have emerged due to various limitations. This study aims to investigate the causal relationship between bone joint-related diseases and TMD using Mendelian randomization (MR).
Methods: We utilized a two-sample MR design, applying pooled genome-wide association study (GWAS) data from six subtypes of bone and joint diseases and TMD.
BMJ Open
January 2025
Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Introduction: Graft-versus-host disease (GvHD) remains a major complication of allogeneic stem cell transplantation (allo-SCT), affecting 30-70% of patients (representing 800 new patients per year in the UK). The risk is higher in patients undergoing unrelated allo-SCT. About 1 in 10 patients die as a result of GvHD or through complications of its treatment.
View Article and Find Full Text PDFJ Biomech
January 2025
Radboudumc, Orthopaedic Research Lab, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
Aseptic loosening is the primary cause of revision in cementless total knee arthroplasty (TKA), emphasizing the importance of strong initial stability for long-term implant success. Pre-clinical evaluations are crucial for understanding implant fixation mechanics and improving implant designs. Finite element (FE) analysis models often use linear elastic bone material models, which do not accurately reflect bone's mechanical behavior.
View Article and Find Full Text PDFClin Cancer Res
January 2025
Stanford University, Palo Alto, CA, United States.
Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in PCa and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.
Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by immunohistochemical staining.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!